Health Canada has approved a new treatment for adult patients with nasopharyngeal carcinoma, a type of throat cancer, according to the manufacturer of the drug.
BeOne Medicines, a global oncology company based in Switzerland, said Health Canada had granted its tislelizumab injection medication a notice of compliance. The drug will be sold under the brand name Tevimbra, according to a Dec. 23 company news release.
BeOne said the injection would be used in combination with gemcitabine and cisplatin as a “first-line treatment” for adults with recurrent or metastatic nasopharyngeal carcinoma.
Dr. Desiree Hao, head and neck medical oncologist and University of Calgary professor, said the approval was a “milestone” and a treatment advancement for those with the cancer….